Abstract: An injector includes a push rod, a magazine tube, a gate, a cannula and an actuator. The magazine tube has a lumen extending from an inlet to an outlet thereof. The magazine tube slidingly receives at least one implant therein. The gate has a closed configuration in which it covers the outlet of the magazine tube and an open configuration in which it does not cover the outlet of the magazine tube. The cannula has a distal end configured to be inserted into an eye. A lumen of the cannula is in fluid communication with the lumen of the magazine tube when the gate is in the open configuration. Actuation of the actuator moves the gate from the closed configuration to the open configuration and causes translation of the pushrod through the magazine tube and the cannula.

Abstract: This invention relates to implantable bioerodible inserts for delivering an active pharmaceutical ingredient to the eye. The invention also relates to methods of treatment using such inserts as well as methods of manufacturing such inserts.

Abstract: The present invention relates to compositions and methods for prevention and treatment of ocular diseases and conditions, particularly glaucoma and ocular hypertension. The compositions and methods of the invention utilize immune-derived moieties that are specifically reactive against the bioactive lipid, sphingosine-1-phosphate, and its variants, which moieties are capable of decreasing the effective concentration of bioactive lipid being targeted. In one embodiment, the immune-derived moiety is a humanized monoclonal antibody that is reactive against sphingosine-1-phosphate.